Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia.

Cividin M, Ayrault O, Sorel N, Séité P, Brizard F, Blanchet O, Mahon FX, Guilhot F, Larsen C, Chomel JC, Brizard A

Laboratoire d'Hématologie, CHU de Poitiers, France. m.cividin@chu-poitiers.fr

Expression of p14(ARF) and p16(INK4a) tumor suppressor genes was investigated in 109 patients with chronic myeloid leukemia (CML). The p14(ARF) and p16(INK4a) mRNA levels were significantly low in patients in chronic phase (CP) at presentation and high in patients treated with interferon-alpha (IFN-alpha), especially in non-responders. A moderate overexpression of p14(ARF) with a normal expression of p16(INK4a) was observed in imatinib-resistant patients. Although protein expression did not consistently match mRNA levels, a role for the two cell cycle regulators in the IFN-alpha signaling pathway is suggested as well as a relation with the resistance to IFN-alpha or imatinib therapy.

Published 21 August 2006 in Leuk Res, 30(10): 1273-8.
Full-text of this article is available online (may require subscription).

© 2004-2008 Glivec Research Today. All Rights Reserved.